Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical’s new cancer treatment proves effective

Aethlon Medical : 18 July, 2007  (New Product)
Aethlon Medical has discovered the Aethlon Hemopurifier is effective in capturing particles that suppress the immune response in cancer patients.
The particles, known as exosomes, are released by solid tumours, lymphomas, and leukemia. Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients.

In studies led by Dr Douglas Taylor at the University of Louisville, 60 percent of circulating exosomes were removed from the blood of ovarian cancer patients during first pass through a small scale Hemopurifier. The capture data was consistent over the course of five different studies.

The ability to reduce circulating exosomes would likely reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy. Dr. Taylor is a recognized authority on the causative effects of immune suppression in cancer patients. He is the credited with the initial characterization of exosomes and is the leading peer reviewed author on the subject.

Based on initial study observations, the Aethlon Hemopurifer is positioned to address the unmet medical need of inhibiting exosome production in cancer patients. As a result, Aethlon will increase the focus of its treatment opportunities to include both the infectious disease and cancer markets.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo